Page 20 - 2 Director Reports (Annexure) 2021.cdr

70-71
synthesis of Atorvastatin calcium crystalline as class of oral hypoglycemics that block the
well as amorphous. Morepen has led several enzyme dipeptidyl peptidase-4 (DPP-4). They
national & international patents pertaining to can be used to treat diabetes mellitus type 2.
its process improvement resulting in The rst agent of the class - sitagliptin - was
appreciable yield gain. It is also having USFDA approved by the FDA in 2006. Glucagon
and CEP approval along with approval from increases blood glucose levels, and DPP-4
Taiwan authority. Enhanced method for inhibitors reduce glucagon and blood glucose
preparation of stabilized amorphous levels. The mechanism of DPP-4 inhibitors is to
Atorvastatin calcium were devised to get better increase incretin levels (GLP-1 and GIP), which
quality. inhibit glucagon release, which in turn
increases insulin secretion, decreases gastric
IV. 4-(4-uorophenyl)-6-isopropyl-2-[(N-methyl-
emptying, and decreases blood glucose levels.
N-methylsulfonyl)amino]pyrimidine- 5-yl-
methanol and aliphatic side chain are the key The company has taken a giant leap in anti-
intermediate for synthesis of Rosuvastatin diabetic category by developing many of the
calcium. Various New polymorphic forms are key drugs in this category like Sitagliptin,
developed for Rosuvastatin calcium which are Saxagliptin, Linagliptin, Vildagliptin &
being explored by various customers worldwide Alogliptin. Morepen is looking ahead to the
for better pharmacokinetic & pharma- patent expiry of Sitagliptin & Saxagliptin that
codynamic properties. Their patents are will open many doors to their generic version.
granted to the company in US and India. A We have discovered new polymorphic
highly efcient process is in place which forms/improved processes of Sitagliptin,
minimize the usage of hazardous chemicals/ Saxagliptin & Linagliptin and are in continuous
catalysts. New polymorphic form M & M2 were lookout for novel polymorphic forms / process
invented and were patented in US. The patent improvements for other gliptin candidates.
for Form M is granted in India & Form M2 is Morepen is looking ahead for its ANDA ling in
soon to be granted. Polymorphic form M soon combination of other drugs such as metformin
will be granted in Europe too. The traditional etc. The mechanism of action of all the drugs in
oral pharmacological therapy for Type 2 body is the same. Morepen has successfully
diabetes mellitus (T2DM) has been based on developed novel as well ecofriendly processes
the prescription of Metformin, a biguanide, as for the preparation thereof. The processes have
rst line antihyperglycemic agent world over. It been streamlined in such a way to minimize the
has been demonstrated that after 3 years of cost as well as efuents, whether solid, liquid or
treatment, approximately 50 % of diabetic gaseous. We are looking forward to our
patients could achieve acceptable glucose technical collaboration with National Institute
levels with monotherapy; but by 9 years this of pharmaceutical education & Research
had declined to only 25 %. Therefore, the (NIPER), India and Cambrex, Germany for
i m p l e m e n t a t i o n o f a c o m b i n e d chemoenzymatic method of synthesis of
pharmacological therapy acting via different various key intermediates of gliptin drugs.
pathways becomes necessary, and its Molecular modelling studies were underway in
combination with a compound of the collaboration with NIPER to see the therapeutic
sulfonylurea group was along decades the effect of various adducts of various gliptin
most frequently employed prescription in drugs.
routine clinical practice. Meglitinides, V. Sodium-glucose co-transporter 2 (SGLT2)
glitazones and alpha-glucosidase inhibitors
inhibitors, also called gliozin drugs, are a new
were subsequently developed, but the ve class of diabetic medications indicated for the
mentioned groups of oral antihyperglycemic
treatment of type 2 diabetes. They have also
agents are associated with variable degrees of been found to show cardiac benets in patients
undesirable or even severe cardiovascular
with diabetes and are being studied for possible
events. The gliptins also called dipeptidyl use in type 1 diabetes. They work by reducing
peptidase 4 (DPP4) inhibitors are an additional
the absorption of glucose via the kidneys so that
group of anti-diabetic compounds with excess glucose is excreted through urination. In
increasing clinical use. Inhibitors of dipeptidyl
conjunction with exercise and a healthy diet,
peptidase 4 (DPP-4 inhibitors or gliptins) are a they can improve glycemic control. They have
been studied alone and with other medications Angiotensin II receptor blockers block the
including Metformin, Sulfonylureas, Nizagara action of angiotensin II. As a result, the
100, Pioglitazone, and Insulin. We medication allows your veins and arteries to
manufacture various gliozin in this class such widen (dilate). Morepen is also producing two
as Dapagliozin, Empagliozin, Canagliozin major sartan drugs - Candesartan &
& Ertugliozin. The process & chemistry Olmesartan. Morepen has devised use of
involved therein is quite similar using a key typical route of synthesis of both the drugs
intermediate namely, 2,3,4,6-Tetrakis-O- which not only ensures the synthesis of these
trimethylsilyl-D-gluconolactone. A highly drugs with lowest possible efuents but also
concise methods are being used to develop with nil amount of nitrosomine impurities like
these new drugs so as to minimize the waste N-nitrosodiethylamine (NDEA), N -
and usage of green solvent or class III solvents nitrosodiisopropylamine (NDIPA), N -
is solicited in each of gliozin drug. Since nitrosoethylisopropylamine (NEIPA) and N -
molecules are chiral, further possibilities of nitroso-N-methyl-4-aminobutyric acid
chemoenzymatic methods is also being (NMBA).
explored to make process totally green /
VIII.The company is looking to enter the US market
ecofriendly. Morepen has been able to
with proposed ANDA Filings for Amlodipine
commercialize the Dapagliozin, Empag-
Besylate, Ezetimibe, Divalproex Sodium &
liozin, Canagliozin & Ertugliozin. Many
Dimenhydrinate. Amlodipine/Ezetimibe is a
process related patents were also led related key antihypertensive molecule which can be
to various Gliozin drugs. Amorphous forms
launched in combination with Atorvastatin or
were also developed in order to capture US/EP Rosuvastatin. Divalproex is a potent anti-
market.
epileptic medication with great sales & volume
VI. Apixaban, Rivaroxaban & Edoxaban Tosylate world over. Dimenhydrinate is a high volume
are anti-coagulant medications used for anti-emetic product with great potential to
treatment and prevention of blood clots and to enter market.
prevent stroke in people with nonvalvular atrial
IX. The company has widened its research
brillation. Specically, they are used to
perspective with focus on developing some of
prevent blood clots following hip or knee
the top 100 molecules from various categories.
replacement and in those with a history of prior
These molecules include Tofacitinib Citrate in
clots. They are used as an alternative to
Anti-arthiritis category, Paliperidone Palmitate
warfarin and does not require monitoring by
which is the primary active metabolite of
blood tests. They are taken by mouth. Both are
risperidone & Brexpiprazole in Antipsychotic
among the largest selling drugs in the world.
Category, Vonoprazan Fumarate in Anti-
A highly concise method is being used to ulcerative category & Elagolix sodium in GnRH
develop these top drugs keeping in mind the antagonist category. Besides these products for
low wastage and efuents and high regulated market Morepen is also developing
throughput. Also, the feasibility of green Saroglitazar Magnesium an Anti-diabetic
solvents usage is being explored to further molecule for India. R&D work is completed on
enhance the process. Most of the side products these drugs.
are easily treated in ETP and are water soluble.
X. Other then these molecules, the company is
No gaseous wastes are generated in the
process throughout. With the patent expiries of looking for a bright future ahead with its
Biotech Division which is still in its early days.
these blockbuster drugs, it has opened a new
opportunity for regulated markets. The company is entering into technical
collaboration with various national &
VII. Sartans or Angiotensin II receptor blockers help international companies for development /
relax your veins and arteries to lower your marketing of COVID-19 vaccines in India. The
blood pressure and make it easier for your company has been a part of ght against
heart to pump blood. Angiotensin is a chemical COVID-19 alongside other pharma companies
in your body that narrows your blood vessels. right from the onset. The company has
This narrowing can increase your blood developed hydrochlorothiazide initially when
pressure and force your heart to work harder. no vaccine was in the scene. Various products of